Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous
08.01.2010
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, January 8, 2010 - Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700) has officially instructed the statutory auditor of
publicly listed Belgian seed manufacturer International Brachytherapy S.A.
(IBt) to convene, as quickly as feasible, a special general meeting of the
shareholders of IBt. Sole item on the agenda is the replacement of IBt
non-executive board member H&H Capital Management BVBA, represented by its
sole director and Creafund representative Herman Wielfaert, by a
representative of Steglitz Medinvest UG (SMI), who together with Eckert &
Ziegler on 28 December 2009 initiated a public take-over bid for IBt. SMI,
which holds about 22% of the shares in IBt, has so far not been represented
on IBt's board at all.
'SMI is a party to the take-over bid and a large IBt shareholder, so it is
natural that it should also nominate at least one member of the IBt board',
explains Andreas Eckert, CEO of Eckert & Ziegler. 'Creafund, on the other
hand, has spent considerable effort and money in suing Eckert & Ziegler and
SMI for a cash offer for IBt shares. Now that we have voluntarily, and at a
substantial effort, complied with Creafund's wishes, we would in any way
expect that Creafund accepts the offer and vacates his board seat.'
Eckert & Ziegler currently owns about 29% of the shares of IBt and is
represented on the board by two non executive directors. Four other
directors of the board are independent. Three are Executive Directors that
compose the management team. Together with the SMI representative the new
board would have ten directors, the maximum amount of incumbents allowed by
IBt's articles of association.
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: karolin.riehle@ezag.de,
www.ezag.de
08.01.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Eckert & Ziegler Officially Requests Special IBt Shareholder Meeting
| Source: EQS Group AG